SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022)
SAB Biotherapeutics' (SABS) quarterly Non-Current Debt came in at $541644.0 in Q4 2022, up 214.84% on a QoQ basis from $172037.0 in Q4 2020.
SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022) Analysis & Trends
SAB Biotherapeutics (SABS) has 2 years of Non-Current Debt data on file, last reported at $541644.0 in Q4 2022.
- Quarterly Non-Current Debt changed N/A year-over-year to $541644.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
- Non-Current Debt rose to $541644.0 in Q4 2022, from $172037.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $541644.0 in Q4 2022 to a low of $172037.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 541,644.00 |
| Dec 31, 2020 | 172,037.00 |